ROCKVILLE, Md.--(BUSINESS WIRE)--Celek Pharmaceuticals announced that it will present an update on its anticancer drug development programs today at the National Cancer Institute (NCI)’s 2012 Investor Forum in Santa Clara, CA. The NCI selected Celek as one of 18 companies from more than 100 applicants to present at this conference. Only companies funded under the NCI’s Small Business Innovation Research (SBIR) program were eligible to apply.
